Leukemia/lymphoma

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... 

Lymphomas not included in Working Formulation mycosis fungoides, mantle cell lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT), anaplastic large cell lymphoma, angiocentric lymphoma, angioimmunoblastic lymphadenopathy (AILD), Castleman s disease, adult T-cell leukemia/lymphoma. 

Ishii E, Kawasaki H, Isoyama K, et al. Recent advances in the treatment of infant acute myeloid leukemia. Leukemia Lymphoma 2003 44 741-748. 

Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 2004 10 7529-7539. 

Leukemia, lymphoma, Hodgkin s disease, or multiple myeloma / Generalized malignancy / Chronic renal failure of nephritic syndrome / Patients receiving immunosuppressive therapy / Organ or bone marrow transplant recipients... 

Keywords Tyrphostins, Protein tyrosine, Kinases, JAK-2 EGF, PDGF BCR-ABL, Psoriasis, Papilloma, Restenosis, Leukemia, Lymphoma... 

Vaccines Yes. Wyeth Vaccine, called VIG or vaccinia immune globulin, one dose by scarification. (Pre- and post-exposure vaccination recommended if greater than three years passed since last vaccine.) Persons who are pregnant, have clinical immunosuppression (such as persons who have undergone heart and other transplant operations and take medicines to control rejection of their new, transplanted organ), eczema, and/or leukemia/ lymphoma would be contraindicated for such vaccine. As one example, the fatality rate for immunosuppressed persons taking such vaccine could be as high as 75 percent or more. 

Jaffrezou, . P., Bettaieb, A., Levade, T., and Laurent, G., 1998, Antitumor agent-induced apoptosis in myeloid leukemia cells a controlled suicide. Leukemia Lymphoma 29 453-463... 

Doxorubicin and dannorabicin are antibiotics made from microorganisms of the family Streptomyces peucetius. The stmcture of these anthracyclines contains an aminosaccarhide residue daunozamine attached to a naphthacenequinone nucleus. Doxorubicin differs from daunorubicin in the presence of a hydroxyl gronp at C14. A nnmber of mechanisms have been suggested in which anthracyclines exhibit cytotoxicity. They canse DNA to denature, are involved in oxidation-rednction reactions, chelate bivalent cations and react with cell membranes, changing their fnnction. They are used for severe leukemia, lymphoma, breast and ovarian cancer, and other solid tumors. 

K3. Kinoshita, K., Kamihira, S., Yamada, Y, Amagasaki, T., Ikeda, S., Momita, S., and Ichimaru, M., Adult T-cell leukemia-lymphoma in the Nagasaki district. In Adult T-Cell Leukemia and Related Disease (M. Hanaoka, K. Takatsuki, and M. Shimoyama, eds.), pp. 167-184. Japan Scientific Societies Press, Tokyo, 1982. 

Shimoyama, M., Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 79,428-437 (1991). 

The alkylating agents can be considered to be cell-cycle independent drugs. They are used for the management of leukemias, lymphomas, multiple myeloma and some carcinoma s and soft tissue tumors, generally as components of drug combination regimens. Cyclophosphamide is also used for its marked immunosuppressant properties. 

The incidence of nonallergic ampicillin eruptions is 40 to 100% in patients with concomitant Epstein-Barr virus (mononucleosis), cytomegalovirus, acute lymphocytic leukemia, lymphoma, or reticulosarcoma. Nonallergic penicillin-associated rashes are characteristically morbilliform (symmetrical, erythematous, confluent, maculopapular) eruptions on the extremities. The onset of typical nonallergic eruptions is more than 72 hours after (3-lactam exposure. The mechanism for the nonurticarial ampicillin rash is not known and is not related to IgE or type I hypersensitivity. Penicillin skin tests are not useful in the evaluation of nonurticarial ampicillin rashes. Patients with a history of nonurticarial ampicillin rashes may receive other (3-lactam antibiotics without greater risk of subsequent serious allergic reactions. 

Lymphoma, breast and ovarian cancer, oat cell lung cancer Acute myelogenous and acute lymphoblastic leukemia, lymphomas Metastatic melanoma, sarcomas, Hodgkin s disease... 

Hematological system (anemia, polycythemia, thrombocytopenia, leukemia, lymphoma, multiple myeloma)... 

Gout results from hyperuricemia i.e. increased serum uric acid levels. Normal serum uric acid level is 1-5 mg/dl. Uric acid is formed in the metabolism of purine. When the blood levels of uric acid are high, it precipitates in joints, cartilage, kidney and subcutaneous tissues and leads to various signs and symptoms. Hyperuricemia is also seen in various leukemias, lymphomas... 

USP3 (Cembidine) leukemia lymphomas toxicity alopecia stomatitis GI disturbance... 

Several reports have described the anticancer activity of curcumin in a variety of cancer cell lines. In vitro studies have established the activity for curcumin against breast, gastric, hepatic, pancreatic, colorectal, urinary bladder, kidney, prostate, cervical, ovarian, uterine, lung, oral, thymic, and skin cancers. Besides these cancer types, curcumin has shown in vitro therapeutic efficacy against hematological cancers including leukemia, lymphoma, and multiple myeloma. One of our early studies established that the antiproliferative effect of curcumin in human breast cancer cell lines, including hormone-dependent, hormone-independent,... 

Neoplastic disease Antilymphocytic effects Leukemias, lymphomas, nasal polyps, cystic tumors... 

As mentioned, interferons also help control abnormal cell proliferation, and these drugs have been approved for use in certain cancers. Interferons are often used as part of the treatment for certain leukemias, lymphomas, and several other forms of cancer (see Table 34-4). Interferon use in cancer chemotherapy is discussed in more detail in Chapter 36. 

---